Atzpodien, J <br/><br/>
Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).  [electronic resource] 

 -  British journal of cancer  Aug 2006 
 - 463-9 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0007-0920 
<br/><br/><label>Standard No.: </label>10.1038/sj.bjc.6603271  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Capecitabine<br/>Carcinoma, Renal Cell--drug therapy<br/>Deoxycytidine--administration & dosage<br/>Disease Progression<br/>Disease-Free Survival<br/>Female<br/>Fluorouracil--administration & dosage<br/>Germany<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--administration & dosage<br/>Interleukin-2--administration & dosage<br/>Isotretinoin--administration & dosage<br/>Kidney Neoplasms--drug therapy<br/>Lung Neoplasms--secondary<br/>Male<br/>Middle Aged<br/>Recombinant Proteins<br/>Survival Analysis